CCL5 and glioblastoma: Using the CCR5 antagonist, maraviroc, we have shown CCL5 and CCR5 drive primary glioblastoma (GB) cells and glioblastoma stem cells (GSCs) invasion and their interactions with stromal MSCs and can be used as repositioned drug for novel clinical trials in glioblastoma.